Our Services
Medical Information
Helpful Resources
Published on: 1/31/2026
Farxiga (dapagliflozin) is FDA-approved for type 2 diabetes, heart failure (both HFrEF and HFpEF), and chronic kidney disease. Major clinical trials show Farxiga reduces hospitalizations, lowers cardiovascular death risk, and slows kidney decline — benefits confirmed even in people without diabetes.
However, Farxiga isn't right for everyone. Common side effects include increased urination, genital yeast infections, and dehydration, while rare risks include diabetic ketoacidosis. Understanding your symptoms is the first step to deciding whether Farxiga — or another treatment — fits your situation.
Because symptoms of heart failure, kidney disease, and diabetes often overlap (fatigue, swelling, frequent urination, shortness of breath), it can be hard to know what's driving how you feel. A free, instant, online symptom check from Ubie Health, built with physicians, can help you identify possible causes and prepare focused questions for your doctor — so your next appointment leads to clearer answers and better next steps.
Reviewed for medical accuracy: 07/09/2026
Not seeing your question? No worries.
Submit your own QuestionFor many years, farxiga was known mainly as a medication for type 2 diabetes. Today, doctors prescribe it for much more than blood sugar control. In fact, farxiga has become an important treatment option for heart failure and chronic kidney disease—even in people who do not have diabetes.
This shift isn't based on hype or marketing. It's grounded in strong clinical research and updated medical guidelines. Below, we'll explain what farxiga is, how it works, why doctors now use it beyond diabetes, and what patients should know before starting it.
Farxiga (dapagliflozin) is a prescription medication that belongs to a class called SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors).
Originally, farxiga was developed to help people with type 2 diabetes lower blood sugar by helping the kidneys remove excess glucose through urine. Over time, researchers noticed something important: people taking farxiga were also having fewer heart and kidney complications.
That observation changed everything.
Farxiga works primarily in the kidneys. It:
But farxiga also has additional effects that help explain its broader use:
These effects are not limited to people with diabetes—which is why farxiga is now prescribed more widely.
Farxiga is now approved to treat heart failure, including:
Major clinical trials showed that farxiga:
Importantly, these benefits were seen even in people who do not have diabetes.
Because of this, cardiologists now commonly prescribe farxiga as part of standard heart failure care.
Farxiga is also approved for chronic kidney disease, including in people without diabetes.
Studies found that farxiga:
Kidney specialists often describe farxiga as a "protective" medication—one that helps preserve kidney function over time rather than simply treating symptoms.
Although farxiga has expanded uses, it remains an important medication for type 2 diabetes.
For diabetes management, farxiga can:
This combination of benefits makes farxiga especially helpful for people with diabetes who also have heart or kidney concerns.
Diabetes affects more than blood sugar. Over time, high glucose levels can damage:
One common complication is nerve damage known as Diabetic Neuropathy, which can cause:
If you're experiencing these symptoms, understanding whether they could be related to Diabetic Neuropathy is an important first step toward getting the right care and protecting your long-term health.
Doctors often choose farxiga because it offers multiple benefits at once:
This "multi-system" effect is why farxiga has become a cornerstone medication in modern care.
Farxiga is generally well tolerated, but it's not risk-free. Common or notable side effects include:
Less common but serious risks can include:
These risks are well known to doctors and are usually manageable with proper monitoring, hydration, and patient education.
Farxiga may not be appropriate for everyone. Doctors use caution or avoid it in people who:
This is why farxiga should only be started under medical supervision.
Medical organizations focused on diabetes, cardiology, and nephrology now recommend SGLT2 inhibitors like farxiga as first-line or early therapy for many patients with:
These recommendations are based on large, well-designed clinical trials published in respected medical journals and reviewed by independent experts.
Farxiga is no longer "just a diabetes drug." It's a medication that helps protect the heart and kidneys—two organs that are closely connected to long-term health and quality of life.
If you:
…farxiga may be part of a treatment plan worth discussing.
Medication decisions should always be individualized. If you have symptoms that could be serious or life-threatening—such as chest pain, severe shortness of breath, fainting, signs of infection, or sudden changes in urination—you should speak to a doctor right away.
Even for non-urgent concerns, it's important to talk with a healthcare professional before starting, stopping, or changing any medication, including farxiga.
A thoughtful conversation with your doctor can help you weigh the benefits and risks and decide what's right for your health now and in the future.
(References)
* McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911304. Epub 2019 Sep 15. PMID: 31502758.
* Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. PMID: 32970396.
* Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 1;387(12):1089-1098. doi: 10.1056/NEJMoa2204791. PMID: 36027734.
* Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. PMID: 30415602.
* Bergmark BA, et al. SGLT2 Inhibitors for Heart Failure and Kidney Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 Mar 7;81(9):895-915. doi: 10.1016/j.jacc.2023.01.009. PMID: 36863777.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.